Johnson & Johnson (NYSE: JNJ) closed Friday's session at $263.81, down 1.42%, in a move that came just before the company released new cancer data on Sunday. At the ESMO Congress 2026, the annual meeting of the European Society for Medical Oncology and one of the oncology field's largest annual stages for late-breaking clinical data, the drugmaker presented Phase 1 results for JNJ-6143, an experimental once-daily pill for prostate cancer, reporting a 75% tumor response rate among patients with measurable disease at the 50 mg dose. Because Phase 1 trials are a drug's first test in humans, results at this stage are early signals that later studies are designed to confirm.

Phase 1 Tumor Response Data

Among patients with measurable disease at the 50 mg dose, 75% achieved a complete or partial tumor response, which works out to 12 out of 16 patients. In early-phase oncology testing, response rates are typically the first indication of whether a drug is active, though they fall short of the effectiveness evidence that larger trials must establish. One news report put the response rate at 69%, but the company's own release states 75%, so that is the figure used here.

The announcement window also included a separate company statement. As relayed in a post from First Squawk on X, Johnson & Johnson said Erleada (apalutamide) treatment before and after surgery reduces the risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer:

JOHNSON & JOHNSON ANNOUNCES ERLEADA® (APALUTAMIDE) TREATMENT BEFORE AND AFTER SURGERY REDUCES RISK OF RECURRENCE OR DEATH BY 62% VERSUS SURGERY ALONE IN HIGH-RISK PROSTATE CANCER — First Squawk (@FirstSquawk) [October 24, 2026https://x.com/FirstSquawk/status/2113978689168052673?ref_src=twsrc%5Etfw)

The pairing is notable because Erleada is already an approved prostate cancer therapy in J&J's portfolio, meaning both announcements speak to the same franchise: one an established medicine, the other an experimental pill built on a new mechanism.

How the PSA Numbers Looked

At the 50 mg dose, 77% of patients had a confirmed PSA (prostate-specific antigen) reduction of at least 50%, while another 48% saw their PSA fall by at least 90%. PSA is a protein commonly tracked to measure prostate cancer activity. The company said 38 patients received the 50 mg dose, although one news report counted 31 evaluable patients, so the totals differ by source.

Patients in the study had received a median of four prior therapies, including chemotherapy and PSMA-targeted radioligand therapy, a heavily pretreated group in which moving the needle is notoriously difficult — precisely the setting where any confirmed activity tends to draw scrutiny from the oncology community.

The most common treatment-related side effects were elevated cholesterol (18%), nausea (16%), and elevated triglycerides (16%). The company said most events were mild to moderate. Four patients, or 11%, interrupted their dose, one patient reduced the dose, and one stopped treatment because of side effects. At the time of the analysis, 71% of patients on the 50 mg dose were still on treatment, with a median follow-up of 5.6 months.

The Drug and the Deal

JNJ-6143, formerly known as HLD-0915, came to J&J through its $3.05 billion acquisition of Halda Therapeutics in 2025. It is the first molecule from the company's RIPTAC platform to reach clinical studies. The drug uses a dual-protein lock between BRD4 and the androgen receptor, a mechanism J&J says triggers cancer cell death. The androgen receptor is a central driver of prostate cancer growth and the target of several existing medicines, including Erleada, and resistance to that class of drugs is a well-documented challenge in advanced disease.

Yusri Elsayed, J&J's global head of oncology, called the results “an encouraging foundation” for continued development. Professor Johann de Bono of the Institute of Cancer Research (ICR) in London said the anti-tumor activity observed in heavily treated patients was meaningful.

The trial was small, however, and the response rates do not show how long patients benefit or whether the drug improves survival. The 50 mg once-daily dose will now advance into a Phase 2 study in metastatic prostate cancer, the molecule's next major test of whether the early signals hold up. The dose-escalation portion of the Phase 1 trial tested doses ranging from 12.5 mg to 150 mg.

Wall Street View

Over the past three months, 18 analysts have rated JNJ, producing a Moderate Buy consensus. The average price target stands at $288.71, about 9% above the current price.

This article originally appeared on CoinCentral.